At present, clinicians usually take drug corrective measures only when CKD patients have intermediate and advanced PEM with abnormal index examinations (such as decreased plasma albumin, anemia, etc.), and the clinical efficacy is not stable. The gene discussed is ALB; the disease is anemia (phenotype).